London, United Kingdom
NCT Number: NCT00985348
Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)
To demonstrate the bioequivalence of a Levetiracetam dry syrup (50% (500mg/1000mg)) versus Levetiracetam 500 mg oral tablet, used as reference, after single dose administration in healthy Japanese subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–55 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Written informed consent dated and signed by subject.
- Healthy male or female Japanese volunteer from the first generation, living outside of Japan for less than 10 years, age range 20 to 55 years inclusive.
- Body Mass Index (BMI) between 18.0 and 28.0 kg/m² inclusive.
Exclusion criteria
- Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method.
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, psychiatric disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication.
- History of drug addiction or presence of drug addiction (positive drug screen) or excessive use of alcohol (weekly intake in excess of 21 units alcohol for male and 14 units alcohol for female; one unit alcohol equals one glass of beer or lager, a glass of wine or a measure of spirits), of psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.
- Heavy caffeine drinker (drinking >5 cups of coffee or equivalent, approximately 500mg of caffeine per day).
- Smokers of more than 10 cigarettes per day or smokers not willing to abstain from smoking while in the clinic for each period.
Treatment and study plan
Levetiracetam (Keppra)
DrugTest Drug :
Levetiracetam dry syrup
Reference Drug :
500 mg oral tablets of Levetiracetam. Frequency: Single Dose
Other names: Keppra
Primary outcomes
-
Cmax (maximum plasma concentration) of Levetiracetam.
Time frame: 36 hours
-
AUC (0-t) (Area under the plasma concentration vs. time curve observed from time 0 h up to the last measurable data point) of Levetiracetam
Time frame: 36 hours
-
AUC (Area under the curve extrapolated to infinity) of Levetiracetam
Time frame: 36 hours
Secondary outcomes
-
tmax (time of maximum plasma concentration) of Levetiracetam
Time frame: 36 hours
-
λz (Terminal elimination rate constant) of Levetiracetam
Time frame: 36 hours
-
t1/2 (Terminal elimination half-life) of Levetiracetam
Time frame: 36 hours
-
MRT (Mean Residence Time) of Levetiracetam
Time frame: 36 hours
-
CL/F (Apparent total body clearance) of Levetiracetam
Time frame: 36 hours
-
Vz/F (Apparent volume of distribution) of Levetiracetam
Time frame: 36 hours
Sponsors and collaborators
Lead sponsor
UCB Pharma
Industry
Registry information
Official study title
Randomized, Monocenter, Open Label, Two-way Cross-over, Single Dose Bioequivalence Study of Two Oral Formulations of Levetiracetam in Healthy Male & Female Japanese Subjects
Important dates
- Study start
- 2009
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Sep 28, 2009
- Registry last updated
- May 16, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details